[A16-30] Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V
Last updated 30.09.2016
Project no.:
A16-30
Commission:
Commission awarded on 13.05.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
The current version 1.1 of the dossier assessment replaces version 1.0 published on 15 August 2016.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-58 | Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30 | Commission completed |
Federal Joint Committee (G-BA)
2016-11-03 A G-BA decision was published.